e-Therapeutics plc
('e-Therapeutics' or 'the Company')
Issue of equity
2 August 2012, Oxford and Newcastle, UK: e-Therapeutics plc (AIM: ETX), the drug discovery and development company, announces that on 2 August 2012 the Company issued and allotted 47,770 ordinary shares of 0.1p each in the Company in order to satisfy the exercise of certain options by staff.
Application has been made to admit the new ordinary shares to trading on AIM and dealings in the new ordinary shares are expected to commence on 8 August 2012. Following admission the number of Ordinary Shares in the Company in issue will be 138,174,237. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, e-Therapeutics plc under the Financial Services Authority's Disclosure and Transparency Rules.
Contacts:
e-Therapeutics plc
Daniel Elger
Tel: +44 (0) 7909 915 068
Panmure Gordon (UK) Limited
Andrew Burnett / Fred Walsh
Tel: +44 (0) 20 7459 3600
-ends-